Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant

Multiple Myeloma (MM)

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma

Br J Haematol

Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Ahmed S, Deeba RE, Tang G, Aljawai Y, Lee HC, Patel KK, Gaballa MR, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O

doi: 10.1111/bjh.70642

Multiple Myeloma (MM)

Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial

Br J Haematol

Rees MJ, Lasica M, Kalff A, Low M, Harrup R, Lai HC, Sidiqi MH, Doo NW, Routledge D, Hocking J, Campbell P, Heenan J, Horvath N, Chien N, Renwick WEP, McCaughan G, Eek R, Lenton DS, Wright T, Gazdar SG, Mazumdar D, Butcher B, Mollee P, Quach H, Australasian Leukaemia and Lymphoma Group

doi: 10.1111/bjh.70851

Multiple Myeloma (MM)

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial

Lancet Haematol

Dytfeld D, Wróbel T, Jamroziak K, Kubicki T, Robak P, Puła A, Walter-Croneck A, Czyż J, Tyczyńska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Łojko-Dankowska A, Matuszak M, Gil L, Puła B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski Ł, Końska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Cooperrider JH, Derman BA, Karrison T, Jakubowiak AJ

doi: 10.1016/S2352-3026(26)00011-6

Multiple Myeloma (MM)

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

Blood Cancer J

Souto Filho JTD, Cantadori LO, Crusoe EQ, Hungria V, Maiolino A

doi: 10.1038/s41408-025-01413-7

Multiple Myeloma (MM)

Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma

Blood Cancer J

Yohannan B, Langworthy BW, Turner LE, Dispenzieri A, Buadi FK, Dingli D, Leung N, Kapoor P, Gonsalves WI, Kourelis T, Cook J, Binder M, Hayman SR, Lin Y, Go RS, Warsame RM, Rajkumar SV, Kumar S, Muchtar E, Alkhateeb HB, Hogan WJ, Matin A, Patnaik MM, Al-Kali A, Mangaonkar AA, Torghabeh M H, Wolf RC, Shah MV, Gertz MA

doi: 10.1038/s41408-026-01537-4

Multiple Myeloma (MM)

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Blood Cancer J

Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD Jr, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ

doi: 10.1038/s41408-026-01469-z

Leukemia

Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients

Blood Cancer J

Alsugair A, Gauto Mariotti E, Alhousani MM, Fathima S, Yousuf M, Bolarinwa A, Foran J, Mangaonkar AA, Litzow M, Murthy H, Sproat L, Palmer J, Matin A, Ayala E, Slack J, Porrata L, Iqbal M, Khera N, Punwani N, Kenderian S, Chhabra S, Hogan WJ, Shah MV, Alkhateeb HB, Gangat N, Patnaik M, Tefferi A

doi: 10.1038/s41408-025-01359-w

Multiple Myeloma (MM)

MRD-guided induction-intensification with daratumumab-carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma

Leuk Lymphoma

Yokoyama D, Minakata D, Fujiwara SI, Honda S, Tominaga R, Noguchi A, Furuki S, Koyama S, Murahashi R, Nakashima H, Hyodo K, Kawaguchi SI, Toda Y, Umino K, Ueda M, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y

doi: 10.1080/10428194.2026.2723847

Multiple Myeloma (MM)

The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review

Leuk Lymphoma

Park H, Robinson J, Flanagan C, Pawlyn C, Jackson G, Jones JR

doi: 10.1080/10428194.2025.2560085

Related content

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma

Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients

MRD-guided induction-intensification with daratumumab-carfilzomib-based regimen followed by ASCT in patients with newly diagnosed multiple myeloma

The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review